gvtcx

PHE_Scientific_Development of an Ovine Polyclonal Immunoglobulin Therapy.

Public Health England Published 9 Feb 2021 Contracts Finder

key details

Value£26,523
Statuscomplete
Category (CPV) 24956000
RegionSouth West
Deadline16 Apr 2020
Contract start17 Apr 2020
Contract end16 Apr 2021
Proceduredirect
SME suitableYes
OCIDocds-b5fd17-54f5f6ce-5a73-4e84-a2f4-5b01513f52b3

Award

SupplierValueDateStatus
The Native Antigen Company £26,523 17 Feb 2021 active

description

This requirement was to develop a rapid and effective therapy against infection by developing an ovine immunoglobulin treatment against the spike protein of Covid 19.

Additional information:

PHE discharges its duties as a Category 1 Responder to emergencies on behalf of the Secretary of State for Health within the scope of the Civil Contingencies Act 2004 (CCA 2004). This urgent requirement is in response to the COVID -19 outbreak for the research of therapeutic antibodies.

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
9 Feb 2021 Award (award) · 944834b2-12a7-4e1a-b7b5-e976a2fe12f8-411795

more from Public Health England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.